We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+23.47%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.49B
AUM Growth
+$497M
Cap. Flow
+$426M
Cap. Flow %
12.21%
Top 10 Hldgs %
38.36%
Holding
80
New
20
Increased
14
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$161M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$139M
3
APLS
Apellis Pharmaceuticals
APLS
+$63.7M
4
DYN icon
Dyne Therapeutics
DYN
+$57.8M
5
NTLA icon
Intellia Therapeutics
NTLA
+$54.5M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$52.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$48.2M
3
RAPT
RAPT Therapeutics
RAPT
+$44.6M
4
ACLX
Arcellx
ACLX
+$40.2M
5
ANAB icon
AnaptysBio
ANAB
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$171M 4.91%
3,479,853
-583,823
-14% -$27M
AMGN icon
2
Amgen
AMGN
$204B
$156M 4.48%
+550,000
New +$161M
APGE
3
DELISTED
Apogee Therapeutics
APGE
$154M 4.42%
2,323,456
– –
INSM icon
4
Insmed
INSM
$26.7B
$130M 3.72%
4,783,679
-566,321
-11% -$15.8M
DYN icon
5
Dyne Therapeutics
DYN
$3.32B
$129M 3.7%
4,555,383
+2,555,383
+128% +$57.8M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$32.1B
$124M 3.56%
+832,310
New +$139M
GH icon
7
Guardant Health
GH
$23.8B
$124M 3.55%
6,000,000
+1,000,000
+20% +$21.4M
ARGX icon
8
argenx
ARGX
$61.2B
$118M 3.38%
300,000
– –
NTLA icon
9
Intellia Therapeutics
NTLA
$1.63B
$116M 3.32%
4,210,784
+1,960,784
+87% +$54.5M
OCUL icon
10
Ocular Therapeutix
OCUL
$2.24B
$116M 3.32%
12,721,460
+3,490,691
+38% +$24.8M
DVAX
11
DELISTED
Dynavax Technologies
DVAX
$113M 3.25%
9,141,660
+2,048,446
+29% +$26.7M
AXSM icon
12
Axsome Therapeutics
AXSM
$11.2B
$104M 2.98%
1,304,721
+304,721
+30% +$25.6M
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$104M 2.97%
1,500,000
-500,000
-25% -$34.4M
GERN icon
14
Geron
GERN
$835M
$101M 2.88%
30,505,929
+922,480
+3% +$2.07M
AUTL
15
Autolus Therapeutics
AUTL
$519M
$97.4M 2.79%
15,272,172
+3,402,875
+29% +$21.2M
FDMT icon
16
4D Molecular Therapeutics
FDMT
$768M
$96.7M 2.77%
3,034,453
+750,081
+33% +$19.1M
ALKS icon
17
Alkermes
ALKS
$7.7B
$94.7M 2.71%
3,500,000
-500,000
-13% -$14.2M
BCYC
18
Bicycle Therapeutics
BCYC
$257M
$86.9M 2.49%
3,490,506
– –
PLRX icon
19
Pliant Therapeutics
PLRX
$70.6M
$85.7M 2.45%
5,750,000
– –
DFTX
20
Definium Therapeutics
DFTX
$5.21B
$62.7M 1.8%
+6,666,667
New +$38M
ABVX
21
Abivax
ABVX
$9.09B
$61.5M 1.76%
4,297,438
– –
VRDN icon
22
Viridian Therapeutics
VRDN
$2.48B
$60.5M 1.73%
3,456,053
-175,675
-5% -$3.41M
IONS icon
23
Ionis Pharmaceuticals
IONS
$7.75B
$59.5M 1.71%
1,373,475
+124,407
+10% +$5.93M
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$58.8M 1.68%
+1,000,000
New +$63.7M
ANIP icon
25
ANI Pharmaceuticals
ANIP
$1.66B
$56.8M 1.63%
822,001
+222,001
+37% +$13.4M
1
2 3 4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Deep Track Capital held 80 positions worth $3.49B, up 17% from $2.99B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deep Track Capital deployed $426M of net new capital in Q1 2024, opening 20 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 550,000 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AnaptysBio, an estimated $35.7M trimmed.

  • Deep Track Capital's largest Q1 2024 buy was Amgen: 550,000 shares worth $156M.
  • Deep Track Capital added most to Dyne Therapeutics in Q1 2024, an estimated $57.8M increase.
  • Deep Track Capital's biggest Q1 2024 reduction was AnaptysBio, cutting an estimated $35.7M.
  • Deep Track Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $52.8M.
  • Deep Track Capital's ten largest holdings make up 38% of its $3.49B portfolio in Q1 2024.
  • Deep Track Capital opened 20 new positions and closed 14 in Q1 2024.
  • Deep Track Capital's portfolio value rose 17% quarter-over-quarter to $3.49B.

Based on Deep Track Capital's 13F filing for Q1 2024, filed 15 May 2024.